In October 2025, Japan's leading genetic testing company A.D.A.M. Innovations and the global AI medical science technology company SOPHiA GENETICS announced a strategic partnership to jointly introduce advanced liquid biopsy solutions to the Japanese market.

Details of cooperation: Both parties initially collaborated to conduct a liquid biopsy genetic test under the name "MSK-ACCESS® powered with SOPHiA DDM™." This test requires only a single blood draw and can detect treatment-related genomic mutations by analyzing circulating tumor DNA (ctDNA).

Localization value: By conducting inspections and analyses locally in Japan, the inspection cycle can be significantly shortened, costs reduced, and Japanese patients can benefit from the advancement of precise oncology. Both parties also plan to develop and commercialize liquid biopsy companion diagnostics (CDx) in Japan, supporting the development of new drugs.

Industry Impact: This partnership combines A.D.A.M. Innovations' expertise in the local market with SOPHiA GENETICS' global AI-driven platform, strongly promoting the adoption of data-driven medicine in Japan and demonstrating a significant step forward for precision cancer care in the country.